Mesalamine in Crohn's Disease: A Prescription the Trials Never Really Supported
A single patient with mild colonic Crohn's disease, testing whether continuing mesalamine reflects real disease control or a habit the underlying trial evidence never actually justified.
Carol N., a 51-year-old woman who directs a high school choir, was diagnosed with mild, left-sided colonic Crohn's disease four years ago after a workup for what she'd assumed was stress-related bowel irregularity during a particularly demanding concert season. She's been on mesalamine since shortly after diagnosis, and for the last two years her symptoms have been quiet enough that she rarely thinks about her diagnosis outside of her twice-yearly follow-up visits — no blood in her stool, normal energy, a calprotectin that's stayed below 100 at every check for a year and a half. Today's visit is routine, prompted only by her insurance's annual prior-authorization renewal for the mesalamine itself, a piece of paperwork that happened to land the question of whether she actually needs the drug back on the table for the first time since she started it.
The paperwork is trivial; the underlying question isn't. Mesalamine's role in ulcerative colitis is well established — it's genuinely effective for both induction and maintenance in that disease. Its role in Crohn's disease has never held up the same way in randomized trials: the Cochrane reviews pooling the available placebo-controlled trials — Lim and colleagues on induction, Akobeng and colleagues on maintenance — found no significant benefit for either, a null result that has held across multiple formulations and dose ranges rather than reflecting one underpowered study.
And yet mesalamine remains one of the most commonly prescribed maintenance drugs for mild Crohn's disease in real-world practice, Carol's own two years of quiet remission among the cases clinicians point to when the trial data comes up. The actual question the group is facing isn't whether she's doing well — she clearly is — it's whether the drug she credits for that is the reason, or whether her disease would look exactly the same without it.
Clinic, an insurance renewal reopens the question
I'd continue the mesalamine. She's had two years of clean remission on it — normal calprotectin, no symptoms, no flares — and a working regimen is its own evidence, whatever the population-level trial data says. I don't think the honest move here is to stop a drug that appears to be working just because the average effect across a pooled analysis came out null.
The trial evidence isn't a single underpowered study we can set aside — the Cochrane reviews, Lim's on induction and Akobeng's on maintenance, each pooled the available placebo-controlled trials and found no significant benefit for mesalamine in Crohn's disease, across multiple formulations and dose ranges. Her remission is real, but crediting the mesalamine specifically, rather than the natural disease course of mild, quiescent Crohn's disease, is exactly the inference that null trial data should make us more cautious about, not less.
I'm not saying she's had no benefit from anything — I'm saying the specific claim 'the mesalamine is doing this' isn't one the trial evidence actually supports, and continuing to renew a prior authorization on that claim treats a null result as if it doesn't exist.
I don't think this needs to be settled as a mechanism question to make a decision. The real choice in front of Carol is what continuing versus stopping actually costs her: continuing means an ongoing prescription, this recurring authorization hassle, and a small but real cumulative medication burden for a drug that may be doing nothing; stopping means testing that directly, with close monitoring, and finding out. Given how stable she's been and how low-risk a monitored trial off mesalamine would be in genuinely mild, quiescent disease, I'd propose exactly that — not because the pharmacologist is right and the gastroenterologist is wrong, but because it's the one path that actually answers the question instead of arguing around it.
Agreed: a monitored taper off mesalamine with calprotectin checked every three months rather than the usual twice-yearly interval, and an explicit plan to restart immediately if calprotectin rises or symptoms return. Not agreed: what a rise during the taper would actually prove. The gastroenterologist would read any relapse as confirmation the drug was working; the pharmacologist would want to see whether restarting mesalamine specifically resolves it, versus disease activity that might have recurred on its own timeline regardless of the trial — a question left for whichever outcome actually happens, not resolved today.